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IL10-driven STAT3 signalling in senescent
macrophages promotes pathological
eye angiogenesis
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Macrophage dysfunction plays a pivotal role during neovascular proliferation in diseases
of ageing including cancers, atherosclerosis and blinding eye disease. In the eye,
choroidal neovascularization (CNV) causes blindness in patients with age-related macular
degeneration (AMD). Here we report that increased IL10, not IL4 or IL13, in senescent eyes
activates STAT3 signalling that induces the alternative activation of macrophages and
vascular proliferation. Targeted inhibition of both IL10 receptor-mediated signalling and
STAT3 activation in macrophages reverses the ageing phenotype. In addition, adoptive
transfer of STAT3-deﬁcient macrophages into eyes of old mice signiﬁcantly reduces the
amount of CNV. Systemic and CD163þ eye macrophages obtained from AMD patients also
demonstrate STAT3 activation. Our studies demonstrate that impaired SOCS3 feedback leads
to permissive IL10/STAT3 signalling that promotes alternative macrophage activation
and pathological neovascularization. These ﬁndings have signiﬁcant implications for our
understanding of the pathobiology of age-associated diseases and may guide targeted
immunotherapy.
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T
he innate immune system plays an integral role in
regulating angiogenesis during development and in
age-associated diseases such as cancers, atherosclerosis
and blinding eye diseases1–3. In the eye, pathological
neovascularization during disease progression is observed in
patients with age-related macular degeneration (AMD)4,5. AMD
is the leading cause of blindness in people over 50 years of age in
the industrialized world and consists of two subsets of disease6.
Dry (non-neovascular) AMD is characterized by yellowish
cholesterol-rich deposits that contain proteolytic fragments of
complement factors underneath the retina7–10. Abnormalities in
cholesterol metabolism and alternative macrophage activation
have been shown to play a signiﬁcant role in chronic
inﬂammation and disease progression in AMD5. Of signiﬁcant
interest is the wet (exudative or neovascular) form of AMD that is
associated with the majority of the vision loss. It is characterized
by the development of abnormal, leaky blood vessels underneath
the retina, a process called choroidal neovascularization (CNV)11.
Over the last two decades, numerous studies have demonstrated
the essential role of innate immunity, especially macrophages,
in regulating CNV in AMD12–15. Furthermore, it has become
increasingly evident that the polarization state of the
activated macrophage determines the pathophysiological fate
of the neovascular phenotype16–19. However, the programmatic
molecular signals that guide macrophage polarization, particularly
during ageing eye diseases, remain unclear17,20,21. The goal of this
study was to identify the molecular signalling mechanisms that
govern senescent macrophage polarization and inﬂammation
causing neovascular proliferation and blindness in age-associated
eye diseases.
Macrophages are incredibly plastic cells that can adapt
their activity based on the surrounding micro-environment,
confounding the precise understanding of their role in regulating
angiogenesis in disease processes17,22,23. There are two dominant
states of macrophage activation described: classical activation
(M1) or alternative activation (M2). M2 macrophages are further
subdivided into M2a and M2c based on the upstream cytokines
that drive their induction and function. M2a activation is induced
by interleukin (IL)-4/IL13, and it has been recently implicated in
the wound-healing process16. M2c activation is induced by
IL10 and leads to the development of a regulatory macrophage
with anti-inﬂammatory activity17. A more recent macrophage
classiﬁcation has been proposed based on their activation
conditions24,25. These new experimental standards further
highlight the diversity of macrophage populations. The
recognition of multiple polarization states led to the discovery
that alternatively activated macrophages, but not M1
macrophages, promoted angiogenesis in tumours and age-
related eye disease14,16,22. In addition, macrophages from mice
18 months or older polarize more readily to an alternatively
activated phenotype14,26. Adoptive transfer of M1-like young
syngeneic macrophages, but not M2-like old macrophages, into
old recipient mice resulted in signiﬁcant reduction of CNV in a
murine model of AMD14. Furthermore, a recent study identiﬁed
that pharmacological inhibition of M2 macrophage polarization
by doxycycline speciﬁcally decreased CNV27. These studies
demonstrate the crucial role of alternative polarization of
macrophages in promoting CNV in the aged eye.
IL10 is a classic anti-inﬂammatory cytokine and its molecular
signalling pathway has been well characterized in macrophages
and T lymphocytes. Secreted IL10 cytokine binds to the
IL10 receptor 1 (IL10R1) on membrane surfaces, and IL10R1
dimerizes with IL10R2 to exert its downstream effects. IL10R2
recruits cytoplasmic protein Jak1 followed by phosphorylation of
tyrosine at position 705 in the STAT3 (705Y-STAT3) molecule.
Phosphorylated STAT3 forms a homodimer, which is then
translocated to the nucleus to facilitate transcriptional regulation
of target genes such as vascular endothelial growth factor A
(VEGF-A), basic ﬁbroblast growth factor-2 and placental growth
factor, all major angiogenic factors. Because aberrant angiogenesis
is implicated in diverse pathological conditions, multiple
therapeutic strategies have aimed at targeting the STAT3
signalling pathway and downstream growth factors. In fact, there
are three drugs targeting VEGF-A that are currently approved
by the US Food and Drug Administration (FDA) for treating
AMD patients with ocular neovascularization. Finally and more
importantly, while anti-VEGF-A therapy has been a crucial
breakthrough in the ability to treat patients with blinding
neovascular eye diseases, the therapeutic regimen is not ideal
and has limitations because (1) genetic ablation of Vegf-a in
macrophages showed no therapeutic beneﬁt in CNV models
implicating factors other than VEGF-A in the macrophage-
mediated promotion of CNV16, (2) treatment requires intraocular
injection every few weeks and (3) not every patient responds to
the treatment possibly due to genetic variance28. Although IL10/
IL10R signalling has been shown as a determinant factor in
macrophage polarization to an M2 phenotype, the exact
mechanism by which ageing transforms them into disease-
promoting cells is not well understood. Therefore, elucidating the
mechanism by which ageing inﬂuences alternative activation of
macrophages and how this process contributes to the progression
of CNV in blinding eye disease remains imperative.
In this study, we investigated the molecular mechanism behind
age-dependent modulation of macrophage polarization and
angiogenic function using mice of various age and genetic
backgrounds. Here we have shown that IL10 and its downstream
STAT3 signalling activity are key regulators of the senescent
macrophage phenotype in the eye. We further demonstrate that
these age-related modulations in macrophage polarization
and function can be rescued by targeting STAT3 activity.
Taken together, our study demonstrates the therapeutic potential
of targeting STAT3 activity in senescent macrophages as an
attractive avenue to restore anti-angiogenic properties of
these cells to prevent vision loss. These ﬁndings may also be
relevant to other disease such as atherosclerosis and cancers
where alternatively activated macrophages promote disease
pathophysiology.
Results
IL10 is elevated in eyes of old mice. In previous studies,
we demonstrated that ageing transformed macrophages from an
M1 to an M2 phenotype14,26. To determine whether these
programmatic changes are secondary to upregulation of speciﬁc
upstream cytokines within the macrophage micro milieu,
we analysed the expression levels of M2-polarizing cytokines
(Il4, Il10 and Il13) by real-time quantitative PCR (qPCR) in the
retina and spleen of young (3 months of age) and old (18 months
of age) mice. In the naive state, RNA isolated from the whole
retina demonstrated an almost threefold increase in Il10
expression in old mice versus young mice. In addition, we
observed a similar level of upregulation in the spleen, suggesting
that the elevated Il10 expression in old mice is not restricted
to the eye, but is rather a systemic phenotype (Fig. 1a
and Supplementary Fig. 1a). In contrast, analysis of other
M2-polarizing cytokines revealed that ageing had no effects on
Il13 expression in either the eye or spleen, and Il4 levels were not
detectable in the eye (Fig. 1b,c). Therefore, Il10 was the only
M2-polarizing cytokine that was upregulated by ageing in diverse
tissues rich in macrophages.
The elevated ocular expression of Il10 suggested that it could be
a critical regulator of macrophage function in age-related eye
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disease. For instance, IL10 production was increased in the retina
of aged mice and the highest levels were associated with areas of
massive macrophage inﬁltration in injury-induced neovascular
complexes (Supplementary Fig. 1b). Next, we explored the effect
of elevated IL10 on the activation state of macrophages isolated
from young and old mice after IL10 or lipopolysaccharides (LPS)
stimulation (Fig. 1d). Western blot analysis demonstrated a
striking phenotypic difference between the two age groups tested.
Old macrophages treated with IL10, as well as LPS, responded via
activation of STAT3 signalling at signiﬁcantly higher amplitude of
intensity than young macrophages (Fig. 1d,e). In addition, the
nuclear factor-kB (NF-kB) pathway, which primarily responds to
LPS treatment but can be activated by IL10, did not show a
marked difference between the two age groups (Fig. 1f). Taken
altogether, these data demonstrate that ageing increases IL10
expression and enhanced IL10-mediated STAT3 signalling in
macrophages (Fig. 1g).
IL10R deﬁciency inhibits vascular proliferation. To further
characterize the potential impact of age-dependent effect of IL10
signalling on macrophage function, we examined the role of the
IL10R in regulating macrophage effector functions. To assess
this, we ﬁrst investigated the effect of selectively blocking IL10R-
mediated signalling in the injury-induced CNV model, a murine
surrogate for neovascularization in AMD. Brieﬂy, old mice
(18 months) received intravitreal injections of neutralizing
antibody against IL10R1 or an isotype control. Mice treated with
anti-IL10R1 antibody (5,606±1,991mm3) showed a signiﬁcant,
ﬁvefold reduction in CNV volume compared with those receiving
the isotype control (26,331±6,192mm3, Po0.0075, Student’s
unpaired t-test; Fig. 2a). These ﬁndings demonstrate the
importance of IL10R-mediated signalling in regulating CNV, and
highlight the potential relevance of increased IL10 in macro-
phages in old mice. Because surface receptor expression is critical










































































































































Figure 1 | Ageing is associated with elevated IL10 in the eye and increased response to IL10 stimulus in macrophages. (a) Il10, (b) Il13 and (c) Il4mRNA
expression of retina–choroid and spleen from 3- (3 Mo) and 18-month-old (18 Mo) mice was measured by real-time qPCR. Values are expressed as
meanþ s.e.m. relative to young (3 Mo) mice. At least three biological replicates were analysed in three independent experiments. (Student’s unpaired
t-test; ***Po0.001, NS (not signiﬁcant) P40.05 compared with 3-Mo-old mice; ND not detected). (d) Peritoneal macrophages from young and old mice
were treated with LPS or IL10 for 18 h. Immunoblot with speciﬁc antibodies for Y705-STAT3 (79/86 kDa), STAT3 (79/86 kDa), phospho-NF-kB P65
(65 kDa) and NF-kB P65 (65 kDa) subunits were analysed from young and old macrophage whole-cell lysate. These are representative blots from three
independent experiments. (e) Immunoblot was quantiﬁed for the phospho-Y705-STAT3 to total STAT3 ratio and (f) for the phospho-P65 to total P65 ratio.
The ratios are normalized to the untreated (UT) samples from each age group. (g) Proposed model: elevated IL10 and enhanced STAT3 signalling promote
alternative activation (M2) in macrophages associated with pro-angiogenic function.
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the surface expression of IL10R1 in young and old macrophages
by ﬂow cytometry. Our data demonstrated that there was no
signiﬁcant difference in IL10R1 expression between young and
old macrophages (Fig. 2b). These ﬁndings indicated that the
enhanced STAT3 activity observed in old macrophages was not
due to increased surface receptor expression, and further
corroborated our previous ﬁndings implicating the importance of
IL10 intracellular signalling in the ageing eye during CNV12.
As IL10R1 binds to IL10R2 to facilitate STAT3-mediated
signalling, and because old macrophages demonstrated prolonged
STAT3 activity after IL10 stimulation, we next investigated the
role of IL10R-mediated STAT3 signalling utilizing IL10r2 /
mice29. First, we conﬁrmed that the macrophages from the
IL10r2 / mouse lacked the ability to respond to IL10 cytokine,
as demonstrated by the absence of Y705-STAT3 activation after
IL10 treatment (Fig. 2c). Next, we assessed the ability of wild-type
(WT) or IL10r2 / macrophages to inhibit vascular
proliferation in vitro using a well-characterized assay of human
microvascular endothelial cell (HMVEC) proliferation. We found
that IL10r2 deﬁciency enhanced the ability of macrophages to
inhibit endothelial cell proliferation (63.63% compared with
34.19% relative to HMVEC alone, Po0.0001, Student’s unpaired
t-test; Fig. 2d). To establish a link between the phenotype
observed in the HMVEC assay and the macrophage polarization
of IL10r2 / macrophages, we performed qPCR to determine
the expression level of M2 polarization markers within these cells.
The IL10r2 / macrophage expressed signiﬁcantly lower levels
of M2 markers, such as Arg1 (Fig. 2e) and Cd163 (Fig. 2f), while
expressing higher levels of M1 markers such as Il6 (Fig. 2g) and
Tnf (Fig. 2h). Given that IL10 is an M2-promoting cytokine that
targets Cd163 and Arg1 genes through STAT3 signalling, it is
conceivable that the IL10r2 / macrophages are less M2-like
due to abrogation of IL10/STAT3 signalling30–32. Furthermore,
IL10r2 / macrophages were resistant to M2 polarization
because these macrophages failed to increase Cd163 or Arg1
expression after IL10 treatment (Supplementary Fig. 2).
Taken together, these data demonstrate the importance of
IL10R2-mediated signalling in determining macrophage
alternative (M2) activation and downstream effects on their
ability to regulate vascular proliferation.
Macrophages deﬁcient in STAT3 inhibit angiogenesis. Both
anti-IL10R1 antibody-mediated rescue and experiment using
IL10r2 / mouse are global approaches to examine polarization
and effector function but lack cell type speciﬁcity. Thus, it is
important to delineate whether IL10 signalling speciﬁcally in
macrophages plays a role in regulating CNV. To do this, we
generated a conditional knockout mouse lacking functional
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Figure 2 | IL10 receptors play a role in regulating CNV, microvascular proliferation and alternative (M2) macrophage polarization. (a) Eighteen-month-
old female mice were treated with anti-IL10R1 or isotype control antibody (Ab) and CNV complex was quantiﬁed. Values are expressed as meanþ s.e.m.
(N45 eyes per group, Student’s unpaired t-test; **Po0.01 compared with isotype control). (b) Surface IL10R1 expression in young and old peritoneal
macrophage was measured using ﬂow cytometry. Macrophages were ﬁrst gated for F4/80 expression followed by IL10R1 detection using speciﬁc
antibodies. Representative data from two individual mice for each age group are shown. (c) Peritoneal macrophage from C57BL/6J (Bl6) or Il10r2 / mice
were treated with IL10. Representative blots are shown from peritoneal macrophages treated with recombinant IL10. b-Actin (42 kDa) was used to
normalize protein loading, and relative phosphorylated STAT3 (79/86 kDa) signalling was expressed as a ratio to total STAT3 (79/86 kDa). Representative
data from three independent experiments are shown. (d) HMVEC proliferation assay of Il10r2 / macrophage showing enhanced inhibition of HMVEC
proliferation compared with age-matched C57BL/6J macrophages. Values are expressed as meanþ s.e.m. relative to lone HMVEC cultures with four
independent experiments. (N44 co-cultures per group per experiment, Student’s unpaired t-test; ***Po0.001 compared with C57BL/6J macrophages).
mRNA expression of (e) Arg1, (f) Cd163, (g) Il6 and (h) Tnf in peritoneal macrophages from age-matched C57BL/6J and Il10r2 / were measured by
real-time qPCR. Values are expressed as meanþ s.e.m. relative to C57BL/6J (Bl6). Data shown are representative of three independent experiments.
N43 biological replicate per group per experiment, Student’s unpaired t-test; *Po0.05, ***Po0.001 compared with C57BL/6JB macrophages.
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macrophage and granulocytes (Stat3F/F;LysMCre)26,33,34. We ﬁrst
veriﬁed that IL10-mediated STAT3 signalling is abrogated in the
knockout macrophage by performing a series of biochemical
characterizations in peritoneal macrophages. Using both
western blotting and immunohistochemistry approaches, we
demonstrated that Stat3F/F;LysMCre macrophages are unable to
respond to IL10 via STAT3 signalling as indicated by the lack of
STAT3 phosphorylation as well as its nuclear translocation
(Fig. 3a and Supplementary Fig. 3). To determine the precise role
of STAT3 activity in the sequential events leading to macrophage
polarization, macrophages were treated with LPS or IL10, and
changes in their activation states were analysed by quantitative
gene expression and enzyme-linked immunosorbent assay
(ELISA). STAT3 deﬁciency in macrophages signiﬁcantly
inhibited the induction of M2 markers such as Arg1 and Cd163
on IL10 stimulation, conﬁrming the key role of STAT3
as a mediator of IL10 signalling and M2 polarization
(Fig. 3b,c). Conversely, LPS treatment induced pro-inﬂammatory
cytokine expression, including IL1b, Il6 and Tnf. Interestingly,
co-treatment with IL10 effectively reduced the mRNA (Fig. 3d)
and protein (Fig. 3e,f) levels of these cytokines in control
macrophages, but not in the Stat3F/F;LysMCre macrophages,
suggesting a deﬁciency in physiological feedback signalling that is
critical for homeostatic regulation of macrophage function. These
data suggest that genetic ablation of STAT3 signalling activity in
macrophages leads to sustained expression of pro-inﬂammatory
cytokines (Supplementary Fig. 4) that is unresponsive to the
anti-inﬂammatory effects of IL10.
Previous studies have shown that an IL10-rich environment in
the eye is amenable to alternative (M2) macrophage activation
and development of CNV14,16. Thus, we explored the
implications of this M2 resistant and M1 prone character of
Stat3F/F;LysMCre macrophage in vivo. When Stat3F/F;LysMCre
mice were examined in the injury-induced CNV model, there was
a marked decrease in CNV volume compared with littermate
controls (7,598±1,061 versus 4,138±996mm3, Po0.0075,
Student’s unpaired t-test; Fig. 4a,b). To further corroborate the
role of STAT3 signalling within the CNV complexes in the eye,
b c
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Figure 3 | Stat3F/F;LysMCre macrophages are resistant to M2 polarization and express persistent pro-inﬂammatory cytokines. (a) Peritoneal
macrophages from control (Stat3F/F) and knockout (Stat3F/F;LysMCre) mice were treated with IL10. Immunoblots for Y705-STAT3 (79/86 kDa) and total
STAT3 (79/86 kDa) expression in cytoplasmic and nuclear lysate are shown. b-Actin (42 kDa) and HDAC (60 kDa) were used as loading controls for
cytoplasmic and nuclear protein, respectively. Representative data from three independent experiments are shown. (b) Arg1 and (c) Cd163 mRNA fold
change in Stat3F/F or Stat3F/F;LysMCre macrophages after 18 h of IL10 treatment in culture was measured by real-time qPCR. Values are expressed in fold
change relative to untreated macrophage as meanþ s.e.m. At least two biological replicates were analysed for three independent experiments. (Student’s
unpaired t-test; ***Po0.001, *Po0.05 compared with Stat3F/F mice). (d) Peritoneal macrophages were treated with LPS or LPS and IL10 co-treatment for
18 h. Real-time qPCR was performed to measure relative suppression of inﬂammatory cytokines, Il1b, Il6 and TNF. (N43 pooled macrophage samples in
independent experiments are shown, Student’s unpaired t-test, ***Po0.001 compared with LPS alone). ELISA for (e) IL6 and (f) TNF was performed to
determine the cytokine concentration in the media after LPS or LPS and IL10 co-treatment. N¼ 3 each; Student’s unpaired t-test, ***Po0.001 compared
with LPS alone, NS (not signiﬁcant) P40.05, compared with LPS alone, ^Po0.001 compared with Stat3F/F.
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we performed immunohistochemistry to demonstrate that the
reduction in CNV was associated with an absence of STAT3
activation in the inﬁltrating F4/80þ macrophages (Fig. 4c). To
demonstrate the cellular and functional role of STAT3 signalling
in macrophages, we performed an HMVEC proliferation assay.
Stat3F/F;LysMCre macrophages demonstrated an enhanced ability
to inhibit HVMEC proliferation compared with littermate
controls (61.81 versus 39.00% relative to HMVEC alone,
Po0.001; Fig. 4d). Interestingly, the level of inhibition was
similar to that obtained when using macrophages depleted for
either the Il10r1 or Il10r2 genes, which further highlights the
signiﬁcant and critical coordination between IL10 and STAT3
signalling in the vascular proliferation (Fig. 2d and ref. 14).
Finally, to further demonstrate the pro-angiogenic role of
STAT3 signalling in macrophage, we performed an intravitreal
injection of control Stat3F/F or Stat3F/F;LysMCre macrophages
into 18 months old mice after CNV induction. Quantiﬁcation of
choroidal neovascular complexes revealed that mice receiving
Stat3F/F;LysMCre macrophages developed signiﬁcantly less CNV
compared with the mice that received control macrophages
(Fig. 4e,f). These results conclusively demonstrate that STAT3
activation is crucial for macrophage regulation of pathological
vascular proliferation and CNV.
As shown above, STAT3 signalling activity is highly associated
with the alternative (M2) polarization of macrophages,
which conﬁrms previous observations regarding angiogenesis
in tumour-associated macrophages35–37. NF-kB and STAT3
signalling pathways are the two main molecular cascades
known to govern M2 polarization in tumour-associated





































































Figure 4 | Stat3F/F;LysMCremice are protected against neovascular proliferation. (a) Laser-induced CNV was performed on Stat3F/F;LysMCre and Stat3F/F
mice. Mice were perfused with ﬂuorescein isothiocyanate–dextran to visualize CNV complex and quantiﬁed. Values are expressed as meanþ s.e.m. N416
eyes for each genotype. Student’s unpaired t-test. ***Po0.00075 compared with Stat3F/F mice. (b) Representative CNV pseudo-volumetric images for
Stat3F/F and Stat3F/F;LysMCre are shown. Areas of CNV quantiﬁed are indicated in white dotted circles. Scale bars, 20mm. (c) A representative
immunohistochemical image of F4/80 (red) and activated Y705-STAT3 (45) in CNV lesion. Inﬁltrating F4/80þ macrophages also express active STAT3
signalling in control but not in Stat3F/F;LysMCre. White dotted circle indicates the proportional size of CNV complex. Scale bars on the main picture and
insets are 100 and 10mm, respectively. (d) HMVEC proliferation assay demonstrates Stat3F/F;LysMCre-enhanced inhibition of HMVEC proliferation in vitro
compared with control macrophages. Values are reported as meanþ s.e.m. relative to lone HMVEC culture. N¼ 20 co-cultures for each genotype.
Student’s unpaired t-test. ***Po0.0005. (e) Representative CNV pseudo-volumetric images for 18-month (Mo)-old mice receiving Stat3F/F or Stat3F/F;
LysMCre macrophage followed by laser-induced CNV are shown. Areas of CNV quantiﬁed are indicated in white dotted circles. Scale bars, 20 mm.
(f) Quantiﬁcation of CNV volume in macrophage adoptive transfer experiment. Values are expressed as meanþ s.e.m. N411 eyes for each genotype.
Student’s unpaired t-test. *Po0.0199 compared with mice receiving control stat3F/F macrophage.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8847
6 NATURE COMMUNICATIONS | 6:7847 | DOI: 10.1038/ncomms8847 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
suggesting a role for NF-kB activation in the regulation of
CNV39,40. However, our data indicated that the NF-kB pathway
in macrophages did not play a role in CNV, as we did not observe
a signiﬁcant difference in NF-kB signalling between young and
old macrophages (Fig. 1d). In addition, macrophage-speciﬁc
knockouts of IKKb (inhibitor of kappa light polypeptide gene
enhancer in B-cells, kinase beta) showed no effect on CNV in vivo
or vascular proliferation in vitro (Supplementary Fig. 5).
5,15-DPP is a potent inhibitor of STAT3-driven angiogenesis.
Having established the foundation that STAT3 is a key regulator
of macrophage activity and function, we sought to reverse the
enhanced CNV phenotype and ameliorate disease burden in old
mice by targeting STAT3 signalling. Pharmacological STAT3
inhibitors have been popular targets for drug development owing
to their potential applications in cancer and liver diseases41,42.
Several studies have demonstrated efﬁcacy of targeting inﬁltrating
macrophages within the CNV lesions13,14,43. To test the
therapeutic beneﬁt of targeting STAT3 in CNV, we used 5,15-
diphenyl-porphine (DPP) because of its high speciﬁcity to STAT3
over other STAT proteins44. Moreover, the drug has been
previously assessed in an animal model for partial hepatectomy,
wherein mice showed excellent drug tolerance to treatment45. We
ﬁrst determined the effect of the 5,15-DPP-mediated targeting of
STAT3 signalling using a murine macrophage cell line
(RAW264.7). Co-treatment of 5,15-DPP with IL10 resulted in a
signiﬁcant reduction (85 versus 45%, Po0.002, Student’s unpaired
t-test) in nuclear Y705-STAT3 expression observed using both
immunohistochemistry and western blotting (Fig. 5a–c).
To validate the functional efﬁcacy of the 5,15-DPP-mediated
inhibition of STAT3, both young and old macrophages were
treated with IL10 alone or in combination with 5,15-DPP. Cells
were then washed before co-culture with HMVEC cells. 5,15-DPP
successfully restored the ability of old macrophage to inhibit
vascular proliferation, but this beneﬁcial effect was not observed
in young macrophages (Fig. 5d,e). The differential drug efﬁcacy in
young macrophages compared with old could be explained by
their STAT3 activation state. Indeed, in young macrophages, the
low response to IL10 treatment in terms of subsequent activation
of STAT3 (Fig. 1d) limited the effectiveness of 5,15-DPP and
its impact on macrophage function. In addition, the active
IL10/STAT3 signalling pathway state and an M2-like phenotype
as seen in old macrophage likely played a role in the efﬁcacy of
5,15-DPP. These data suggest that 5,15-DPP-mediated inhibition
of STAT3 signalling in old macrophages is therapeutic and
restores the capacity of these cells to inhibit vascular proliferation,
a crucial process involved in development of CNV.
To determine whether the anti-angiogenic and therapeutic
effects of 5,15-DPP could be demonstrated in vivo, we investigated
its effect on CNV. Old mice were pretreated with either vehicle
(dimethylsulphoxide, DMSO) or 5,15-DPP via intraperitoneal (i.p.)
injection for 5 days before laser injury, and the mice continued to
receive daily injections until analysis for CNV volume on day 7.
The drug-treated animals demonstrated a signiﬁcant reduction of
CNV by almost threefold versus DMSO-treated controls
(13,873±1,601 versus 5,151±955mm3, Po0.0001, Student’s
unpaired t-test; Fig. 5f,g). This therapeutic beneﬁt can be at least
partially attributed to the reduced STAT3 signalling in inﬁltrating
macrophages because western blot analysis of peritoneal macro-
phages isolated from mice treated with 5,15-DPP showed lower
STAT3 signalling activity compared with DMSO controls
(Supplementary Fig. 6). Taken together, these experiments have
established that the ability to switch phenotypic state of old
macrophages is a valuable tool to reprogramme them into anti-
angiogenic cells with therapeutic potential.
SOCS3 is reduced in old macrophages. Suppressor of cytokine
signalling 3 (SOCS3) is a well-known target of STAT3-driven
signalling after IL10 stimulation and acts as a feedback regulator
of IL10 production46. It was recently reported that SOCS3 acts as
an endogenous anti-angiogenic factor in endothelial cells during
retinopathy of prematurity47. Based on these ﬁndings, we sought
to determine whether the SOCS3 regulatory pathway was
involved in the effects of STAT3 signalling on macrophage
polarization and CNV. First, we evaluated SOCS3 expression in
Stat3F/F;LysMCre and control macrophages after IL10 treatment.
As shown in Fig. 6a, IL10 treatment in control macrophages
induced both SOCS3 and Arg1 expression by over six- and
twofold, respectively, suggesting that under normal conditions in
young macrophages, SOCS3 may be co-activated by IL10
treatment along with other M2 markers such as Arg1.
Interestingly, while Stat3F/F;LysMCre macrophages did not
respond to IL10 treatment, as evidenced by a lack of changes in
SOCS3 or Arg1 expression, the baseline expression of SOCS3 was
signiﬁcantly higher than littermate controls (Fig. 6a–c).
The differential SOCS3 expression in STAT3 knockout
macrophages led us to investigate whether baseline expression
of SOCS3 determined the responsiveness to IL10 cytokine and the
strong M2-like phenotype found in old macrophages. Analysis of
Socs3 gene expression in young and old macrophages revealed
that old macrophages expressed signiﬁcantly lower SOCS3 and
higher levels of M2 marker genes, such as Arg1, than young
macrophages, as measured by real-time qPCR (Fig. 6d,e),
demonstrating an inverse relationship between classical M2
markers and SOCS3 expression in aged macrophages. As SOCS3
is also known to be a target gene regulated by STAT3 signalling
after LPS or IL10 treatment, we investigated how age affected
responsiveness to LPS and IL10 with respect to SOCS3
induction46. When young macrophages were treated with either
LPS or IL10, SOCS3 protein levels were signiﬁcantly elevated. On
the other hand, induction of SOCS3 in old macrophages after LPS
or IL10 treatment was minimal (Fig. 6f,g). These data suggest that
old macrophages exhibited not only a lower baseline expression
level of SOCS3 but also defective regulation of SOCS3 expression
on IL10 treatment resulting in enhanced STAT3 activity. These
results provide new evidence implicating dysregulated SOCS3
expression and activity in old macrophages as a possible
mechanism contributing to sustained STAT3 activation and
ultimately leading to M2 polarization. To further investigate the
age-dependent increase of IL10 production in macrophages, we
examined the levels of several molecular regulators of IL10
expression in immune cells48,49. In senescent macrophages, the
expression of the transcription factor FBJ osteosarcoma oncogene
(FOS) is signiﬁcantly higher as compared with young
macrophages (Fig. 6h). The upregulation of FOS may explain
the anti-inﬂammatory proﬁle of aged macrophages associated
with increased IL10 production.
Activation of macrophage STAT3 signalling in AMD patients.
The above experiments demonstrate that during ageing, excessive
IL10 expression and STAT3 activation are the determinants of
M2 macrophage polarization and the pro-angiogenic and disease-
promoting phenotype observed in mice. In the next set of
experiments, we investigated whether these cellular and molecular
phenotype ﬁndings are relevant to the monocytes/macrophages
of patients diagnosed with neovascular AMD. To do this,
we examined STAT3 activation in human peripheral blood
mononuclear cells (PBMCs) isolated from wet AMD (age range
67–87 years, n¼ 10) and non-AMD age-matched donors
(58–77 years, n¼ 9). Western blot analysis displayed a remark-
ably higher expression of phospho-STAT3 proteins in AMD
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patients compared with controls (Fig. 7a,b), conﬁrming the
ﬁndings in mice and suggesting a link between STAT3 activation
in macrophage and neovascular AMD.
Because there is no clear evidence that PBMCs in humans
necessarily reﬂect the disease pathophysiology in CNV in eyes of
patients with AMD, we further characterize the involvement
of STAT3 activation in situ using an immunohistochemical
approach. Choroidal neovascular membranes surgically removed
from AMD patients as part of their usual therapy were stained to
investigate the inﬁltrating macrophage subpopulation. CD68 and
CD163 are widely accepted markers used to identify human M1
and M2 macrophage populations, respectively, in numerous
age-related diseases50–52. Using these surface marker proteins
as reference, we noted that the majority of cells that were
CD163-positive expressed nuclear phospho-STAT3 protein
while CD68-positive macrophages did not express prominent
phospho-STAT3 expression (Fig. 7c). In addition, the number of
M2 macrophages was far greater than M1 macrophages in the
neovascular membranes (Fig. 7d). These immunohistochemical
data are a strong indication of a potential relationship between
STAT3 signalling and the M2 macrophage phenotype found in
CNV from eyes of patients with AMD. Although CD68þ and
CD163þ macrophages were detected in neovascular membranes,
there was no activation and nuclear translocation of P65-NF-kB
(Fig. 7e). These ﬁndings further conﬁrm that in macrophages,
NF-kB signalling pathway is not critical for the regulation of
CNV (Supplementary Fig. 5). Given the central role of VEGF in
modulating pathological vascularization53, we analysed its
cell-speciﬁc production in CNV membranes. Our current data
indicate that VEGF is secreted in the neovascular complex and its
production is not restricted to a macrophage subpopulation
(Fig. 7f). VEGF staining was observed in CD68þ macrophages
and CD163þ macrophages.
Discussion
The present study demonstrates that STAT3 signalling is an
important determinant of alternative M2 activation in senescent
macrophages and promotes angiogenesis in blinding eye diseases
















































































































Figure 5 | 5,15-DPP is an effective STAT3 inhibitor and blocks IL10-mediated signalling in macrophages leading to altered regulation of CNV.
(a) 264.7 RAW cells were treated with IL10 or IL10 with 5mM 5,15-DPP for 1 h. Immunohistochemical analysis was used to visualize and quantify
nuclear Y705-STAT3 expression and normalized to total DRAQ5 nuclear-positive cells. Values are expressed as meanþ s.e.m. from a minimum of ﬁve
independent cultures. One-way analysis of variance with a Tukey’s multiple comparison test. **Po0.01 compared with IL10 treated. (b) Representative
immunohistological images of RAW cells stained for F4/80 (red) and Y705-STAT3 at baseline, after IL10 treatment and IL10 and DPP co-treatment. Scale
bars, 20mm. (c) Representative immunoblots of Y705-STAT3 (79/86 kDa), STAT3 (86 kDa) and b-actin (42 kDa) in whole-cell lysate from untreated, IL10
treated, IL10 and DPP co-treated, and DPP-treated macrophages whole-cell lysate. (d) Young or (e) old peritoneal macrophages were untreated, pretreated
with IL10 or co-treated with IL10 and 5,15-DPP before HMVEC proliferation assay. Values are expressed as meanþ s.e.m. relative to untreated cultures.
N¼4. One-way analysis of variance with a Tukey Kramer post test. **Po0.01 compared with untreated group. (f) Eighteen-month (Mo)-old female mice
were either treated with daily DMSO or 5,15-DPP (15mg kg 1) injections for 5 days before and 6 days after CNV injury. Mice were perfused with
ﬂuorescein isothiocyanate–dextran to visualize CNV complex and to quantify CNV volume. Values are expressed as meanþ s.e.m. N¼ 9 eyes for each
treatment group. Student’s unpaired t-test. ****Po0.0001 compared with DMSO-treated mice. (g) Representative CNV pseudo-volumetric image of
mouse treated with DMSO or DPP. Areas of CNV quantiﬁed are indicated by white dotted circles. Scale bars, 20mm.
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micro-environment in the eye and are more susceptible to
IL10 cytokine stimulation, as evidenced by prolonged STAT3
activation. Second, loss-of-function approaches targeting the
IL10/STAT3 pathway utilizing genetic and antibody-mediated
modalities resulted in a decrease in angiogenesis in vivo and
in vitro. Third, macrophages with either dysfunctional Il10r2 or
Stat3 genes displayed lower expression of M2 markers such as
Arg1 and Cd163, and these cells were resistant to alternative M2
activation after IL10 stimulation. Fourth, M2 polarization and the
disease-promoting pro-angiogenic environment in the eyes of old
mice was pharmacologically rescued by 5,15-DPP, a potent
inhibitor of STAT3. Fifth, we discovered that baseline expression
of SOCS3 is a critical component that predicts macrophage
polarization within an IL10-rich environment. Last and perhaps
most relevant, human choroidal neovascular membranes
obtained from eyes of AMD patients were not only rich with
CD163þ M2 macrophages but these macrophages also expressed
nuclear phospho-STAT3 conﬁrming activation. Taken together,
we have elucidated the role of STAT3 signalling in regulating
M2 alternative activation in senescent macrophages and their
function in impaired regulation of angiogenesis in blinding eye
diseases such as AMD.
It has been consistently demonstrated that senescent macro-
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Figure 6 | SOCS3 is a key regulator of the CNV phenotype. (a) Stat3F/F and Stat3F/F;LysMCre macrophages were treated with IL10 for 18 h. Representative
immunoblots for Y705-STAT3 (79/86 kDa), STAT3a (86 kDa), SOCS3 (27 kDa) and Arg1 (40 kDa) are shown. Relative (b) SOCS3 (26 kDa) and
(c) Arg1 (40 kDa) expression to b-actin (42 kDa) was normalized to untreated (UT) Stat3F/F samples. Mean values are indicated underneath each blot.
N42 biological replicate per group. Real-time qPCR for (d) Socs3 and (e) Arg1 expression in young and old macrophages. Values are expressed as
meanþ s.e.m. N45 biological replicates, ****Po0.0001, **Po0.01, Student’s unpaired t-test, compared with 3-month (Mo)-old macrophage. Young and
old peritoneal macrophages were treated with LPS or IL10 for 18 h. (f) Representative immunoblots for SOCS3 and b-actin expression from whole-cell
lysate. (g) Relative SOCS3 expression to b-actin was normalized to 3 Mo macrophage that was UT. N42 biological replicate per group. (h) Quantitative
mRNA analysis of adenosine 2B receptor (A2BR), activating transcription factor 1 (ATF1), CCAAT/enhancer binding protein-b (C/EBPb), cAMP response
element-binding protein (CREB), FOS, MAF and speciﬁc protein 1 (SP1) in peritoneal macrophages isolated from young or old macrophages.
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CD163 accompanied with reduced levels of M1 markers such as
IL1b, tumour-necrosis factor (TNF)-a, chemokine (C-C motif)
ligand 2 (CCL2), matrix metallopeptidase 9 (MMP9) and IL6
compared with young at baseline14,26. Our data indicate that the
balance between SOCS3 and STAT3 signalling is compromised in
senescent macrophages and which might explain why old mice
are more susceptible to CNV. In previous studies, it has been
demonstrated that pro-inﬂammatory cytokine IL6 and anti-
inﬂammatory cytokine IL10 share the same STAT3 signalling
pathway, which induces SOCS3 expression. SOCS3 then targets
GP130, a receptor for IL6, but not IL10R, and this difference in
receptor targeting by SOCS3 results in shorter IL6-driven STAT3
activity, while IL10-driven STAT3 activation is prolonged54. We
speculate that decreased SOCS3 expression in the senescent
macrophages favours more prolonged IL10/STAT3 signalling.
The importance of this kinetic difference has been reported in
previous thermodynamic and biological experiments54,55. Under
pathological conditions, reduced expression of SOCS3 has been
associated with various human cancer cells where STAT3 is
constitutively activated56–58. Therefore, further investigation is
required to understand the regulation of SOCS3 in pathological
states.
Identiﬁcation of markers for alternatively (M2) activated
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Figure 7 | Higher STAT3 activation is observed in PBMCs and in CD163-positive eye macrophages of patients with wet AMD. (a) Human PBMCs were
isolated from wet AMD or age-matched non-AMD (CON) donors. Whole-cell lysates were then subjected to western blotting analysis. Two representative
blots from each group are shown. Relative value of protein expression to b-actin was normalized to CON as shown underneath each blot and (b)
quantiﬁcation of immunoblots is shown. (n45 donors samples, *Po0.05, Student’s unpaired t-test, compared with age-matched non-AMD donors).
(c) Choroidal neovascular membrane of human donor was subjected to immunohistochemical analysis for the presence of CD68þ (green, top) and
CD163þ (green, bottom). Insets show higher magniﬁcation of cells co-stained with polarization markers and nuclear Y705-STAT3 (red) in CD163þ cell.
DAPI (blue) was used to counter stain the nuclei. Scale bars are 20 and 5 mm for lower and higher magniﬁcation, respectively. (d) Quantiﬁcation of CD68
and CD163 in human choroidal neovascular membrane. Graph shows the meanþ s.e.m. of cells identiﬁed in a given visual ﬁeld, N¼6 independent sections.
(e) Choroidal neovascular membranes were stained with antibodies against P65 and macrophage markers CD68 (upper panel) or CD163 (lower panel).
(f) VEGF immunostaining of choroidal neovascular membranes and dual-labeling with anti-CD68 or CD163. Nuclei were stained with DAPI. Scale bars,
20mm.
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macrophage cell type so as to investigate disease pathogenesis
accurately. In our study, the selective usage of CD163 and Arg1 as
markers for M2 alternatively activated macrophages with STAT3
signalling helped us hone in on the direct relationship between
CD163 and STAT3 activity. The CD68 transmembrane protein
marker has been used to identify macrophages in human
pathology. It is particularly interesting that inactivation of STAT3
polarize macrophages to a pro-inﬂammatory phenotype asso-
ciated with a higher expression of M1 markers. An earlier study
reported that CD68-positive macrophages isolated from human
CNV co-express TNF and IL1-b, but not VEGF52. The negative
regulation of STAT3 signalling on TNF expression is a well-
characterized phenomenon: thus, the CD68 macrophage
characteristics observed in our study and previously reported by
Oh et al. support our current model of alternative (M2) activation
of the senescent macrophage in human disease12,51. More
interestingly, inﬁltration of CD68-positive macrophage has been
associated with AMD patients that received intraocular anti-
VEGF therapy59. It is tantalizing to speculate that the therapeutic
beneﬁts of the anti-VEGF agents may be partly attributable to an
anti-angiogenic effect of inﬁltrating CD68þ M1 macrophages in
the eye.
Interestingly, adoptive transfer of STAT3-deﬁcient macro-
phages in the eye of old mice resulted in signiﬁcant reduction of
pathological angiogenesis. The ability of these macrophages to
inhibit CNV in a pro-angiogenic micro milieu demonstrated how
macrophage polarization induced by STAT3 signalling regulates
vascular proliferation in a pathological context.
In summary, our studies show that age-associated changes in
IL10-driven STAT3 signalling promote alternative (M2) polariza-
tion in old macrophages. Both retinal micro-environmental
changes and autonomous changes in macrophage response to
IL10 signalling contribute to a pro-angiogenic M2 phenotype.
In our models of angiogenesis, sustained STAT3 signalling in
senescent macrophages channels M2 polarization and promotes
neovascularization. These ﬁnding are reproducible both
systemically in PBMCs and eye macrophages obtained from
human patients with blinding eye disease AMD characterized by
aberrant neovascularization. Of signiﬁcant interest is the ﬁnding
that impaired regulatory function and polarization of old
macrophages is therapeutically modiﬁable. Together, these data
suggest that M2 macrophage-speciﬁc targeting of STAT3
signalling pathway may lead to novel therapies to treat CNV in
AMD and potentially other diseases such as atherosclerosis and
cancers where abnormal proliferative angiogenesis is pathogenic.
Methods
Animals. All animal experiments were approved by the Animal Studies Committee
of Washington University in St Louis School of Medicine, and performed under all
Animal Care and Use guidelines. Young female C57BL/6J mice (age o3 months)
and old female C57BL/6J mice (age 418 months) were purchased from The
Jackson Laboratory (Bar Harbor, ME) and the National Institute of Aging,
respectively. Il10r2 / mice (C57BL/6J) were generously provided by Dr Paul
Allen from Washington University in St Louis. The macrophage-speciﬁc Stat3F/F;
LysMCre (C57BL/6J) line was generated by breeding Stat3F/F mice, provided by
Dr Shizuo Akira (Osaka University, Japan60), with LysMCre mice (The Jackson
Laboratory). The IkkbF/F (C57BL/6J) mouse line was provided by Dr Michael
Karin of University of California San Diego61. All mice bred and used for these
experiments (males and females) were screened for rd1 and rd8 mutations using
published protocols to assure that only mice with a WT background were used for
the experiments62,63.
Cell culture and human PBMCs. The mouse monocyte/macrophage RAW264.7
cell line was purchased from American Type Culture Collection (ATCC) and
cultured in Dulbecco’s minimum essential medium (Life Technologies, Carlsbad,
CA) with 10% fetal calf serum (Atlanta Biologicals, Flowery Branch, GA), 1%
penicillin and streptomycin (Life Technologies), 1% non-essential amino acids
(Life Technologies), and 1% sodium pyruvate (Life Technologies) and GlutaMax
(Life Technologies). Dermal HMVECs were purchased from Lonza (Walkersville,
MD) and cultured in EGM2V media. Peritoneal macrophages were isolated 5 days
after i.p. injection of 4% thioglycollate (Sigma-Aldrich, St Louis, MO). Isolated
macrophages were allowed to recover in RPMI-1640 media (Life Technologies)
with 10% FBS, and 1% penicillin and streptomycin overnight. Cells were then
scraped and replated according to the protocol described below. Human PBMCs
were isolated from donors with neovascular AMD or age-matched controls. This
study was approved by the Human Research Protection Ofﬁce of Washington
University School of Medicine in St Louis, and informed consent was obtained
from all blood donors. PBMCs were ﬁrst collected in a Cell Preparation Tube with
sodium citrate Vacutainer (Becton, Dickinson and Company, Franklin Lakes, NJ)
PBMCs were isolated and washed according to the manufacturer’s protocol and
stored in  80 C until experimental use.
HMVEC proliferation assay. HMVEC proliferation assay was performed
according to previously described methods26,64. Brieﬂy, HMVEC (3 103 cells)
were cultured in 96-well round-bottomed plates and allowed to adhere to the plate
overnight. Cells were then co-cultured with peritoneal macrophage (1:25 ratio) and
media containing 1 mCiml 1 [3H] thymidine (PerkinElmer, Shelton, CT). For the
STAT3 inhibition experiment, macrophages were cultured in media containing
5 mM 5,15-DPP (Sigma-Aldrich) overnight, washed with PBS, and viable cells were
counted before being co-cultured with HMVECs. After 18 h, cells were harvested
onto glass ﬁbre ﬁlters (Packard) and incorporated [3H] thymidine was counted
using TopCount (PerkinElmer).
Real-time PCR and gene expression analysis. Total RNA was prepared from
spleen, peritoneal macrophages, retina and choroid using either the RNeasy mini
kit or the RNA universal kit (Qiagen, Valencia, CA). Isolated RNA was quantiﬁed,
and 2.0 mg of RNA was converted to cDNA using the High Capacity cDNA Reverse
Transcription kits (Applied Biosystems). PCR ampliﬁcation of cDNA was per-
formed using Taqman probe-based gene expression assay (Applied Biosystems) as
previously described. The following probe sets were used: ActB, Mm00607939_s1;
Tnfa, Mm00443258_m1; IL6, Mm00446190_m1; Il1b, Mm01336189_m1; Ptgs2,
Mm00478374_m1; Ccl2, Mm00441242_m1; Mmp9, Mm00442991_m1; IL10,
Mm99999062_m1; Cd163, Mm00474091_m1; Nos2, Mm00440502_m1; IL4,
Mm00445259_m1; IL13, Mm0043434204_m1; Arg1, Mm00475988_m1 and Socs3,
Mm00545913_s1. Gene expression levels were normalized to a housekeeping gene
either ActB or Gapdh followed by Student’s unpaired t-test for statistical analysis.
For the gene expression analysis after IL10 and LPS treatment fold change in












































Figure 8 | Mechanism of STAT3-mediated regulation of macrophage
polarization and their ability to regulate angiogenesis. Proposed role of
baseline SOCS3 (red) expression and IL10 (blue)-mediated STAT3 (green)
signalling in ageing macrophages. Low baseline SOCS3 expression in old
macrophages leads to increased susceptibility to IL10-mediated STAT3
signalling that polarizes macrophages towards M2 alternative activation.
This change in polarization promotes abnormal angiogenesis.
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ELISA. Peritoneal macrophages (1 106) were seeded onto six-well plates and
cultured overnight. Cells were then treated with 100 ngml 1 LPS, 100 ngml 1
LPS plus 100 ngml-1 of recombinant IL10 or left untreated. Media were collected
and processed for ELISA according to the manufacturer’s protocol (R&D Systems,
Minneapolis, MN). Media samples were diluted so the signal fell within the
dynamic range of detection established in the standard curve provided. Con-
centration of cytokines was further normalized to the total protein of cells where
culture media was collected. The experiment was repeated three times.
Blood was collected from the mandibular vein of young or old mice and further
processed to separate the serum according to the manufacturer’s protocol (BD, NJ).
Samples were then processed for IL10 ELISA (R&D Systems).
Immunohistochemistry. Peritoneal macrophages or RAW cells were cultured on
chambered glass-bottomed slides (Nalgene Nunc International, Rochester, NY). Cells
were then treated with 100 ngml 1 LPS (Sigma-Aldrich), 100 ngml 1 IL10
(Peprotech, Rocky Hill, NJ), a combination of both, or 5mM 5–15-DPP
(Sigma-Aldrich). After treatment, cells were processed for immunostaining accord-
ing to the manufacturer’s protocol (Cell Signaling Technology, Beverly, MA). Brieﬂy,
cells were washed with PBS and ﬁxed with 4% paraformaldehyde (Electron Micro-
scopy Sciences, Hatﬁeld, PA) followed by cold 100% methanol (Sigma-Aldrich). Cells
were then blocked with 5% goat serum (Sigma-Aldrich) plus 0.3% Triton X-100
(Sigma-Aldrich) for 1 h and incubated with primary antibodies against Y705-Stat3
(1/200; no. 9145, Cell Signaling Technology), NF-kB P65 (1/400; no. 8242, Cell
Signaling Technology) and/or F4/80 (1/500; MCA497G, Serotec, Raleigh, NC)
overnight at 4 C. Cells were then washed and incubated with the secondary antibody
conjugated with Alexa-488 (1/500) or Alexa-546 (1/500). After the last wash, cells
were covered with mounting media containing DAPI (4,6-diamidino-2-pheny-
lindole; Vectashields, Vector Laboratory, Burlingame, CA) or DRAQ5 (no. 4084, Cell
Signaling Technology) for nuclear staining and sealed with glass coverslip for con-
focal analysis with a Zeiss LSM510 microscope (Thornwood, NY). Acquired images
were then processed in ImageJ (National Institutes of Health, Bethesda, MD) to
create either a single-ﬁlter image or a merged image.
For human choroidal neovascular membrane staining, 4 mm parafﬁn sections
were deparafﬁnized, rehydrated with graded ethanol and subjected to antigen
retrieval in citric acid-based unmasking solution (Vector Labs) for 3min in a
decloaking chamber (Biocare Medical, Concord, CA). After cooling at room
temperature (RT), slides were washed in PBS and tissues were blocked (3% normal
goat serum and 5% BSA in PBS) for 30min at RT in a humidiﬁed chamber. Tissues
were probed for Y705-STAT3 (1/400; no. 9145, Cell Signaling Technology), along
with CD163 (1/200; MCA1853, Serotec) or CD68 clone kp1 (1/200; Dako,
Carpinteria, CA) overnight at 4 C in a humidiﬁed chamber. After washing in PBS,
tissues were incubated with DyLight 594-conjugated goat anti-rabbit (Novus,
Littleton, CO) and AlexaFluor-488 goat anti-mouse secondary antibodies (1/500)
for 1 h at RT. Slides were again washed in PBS, mounted using SlowFade Gold with
DAPI (Invitrogen) and imaged using UPlanAPO  100, numerical aperture¼ 1.35
oil immersion objective on an Olympus Bx51 microscope (Center Valley, PA)
equipped with a SPOT RT Slider digital camera (Sterling Heights, MI).
Western blot analysis. Whole-cell lysate was extracted from mouse peritoneal
macrophage using RIPA buffer (50mM Tris (pH¼ 7.4), 150mM NaCl, 1% EDTA,
1% NP-40 and 0.1% SDS, all purchased from Sigma-Aldrich) with 100
phosphatase and proteinase inhibitor (Thermo Fisher Scientiﬁc, Waltham, MA).
An amount of 20 mg lysate was resolved using NuPage gradient gels (Life
Technologies) and transferred to nitrocellulose membranes (Whatman) according
to manufacturer’s instructions. Membranes were blocked in 2% non-fat milk
(Bio-Rad) for 30min at RT and then incubated with antibodies against STAT3
(1/1,000, no. 9139, Cell Signaling Technology), STAT3a (1/1,000; no. 8768, Cell
Signaling Technology), Y705-STAT3 (1/2,000, no. 9145 or 1/1,000, no. 9138,
Cell Signaling Technology), P65 (1/1,000; no. 8242, Cell Signaling Technology),
phospho-P65 (1/1,000; no. 3033, Cell Signaling Technology), IKKb (1/1,000;
no. 2684, Cell Signaling Technology), phospho-IkB (1/1,000; no. 9246, Cell
Signaling Technology), phospho-IkB (1/1,000, no. 9242, Cell Signaling
Technology), IKKb (1/1,000; no. 2684, Cell Signaling Technology), Arg1 (1/1,000;
no. 9819, Cell Signaling Technology) SOCS3 (1/1,000; no. 2923, Cell Signaling
Technology), histone deacetylase (HDAC) (1/1,000; no. 5113, Cell Signaling
Technology), b-actin (1/10,000; A2228, Sigma-Aldrich) and GAPDH (1/5,000;
SAB3500247, Sigma-Aldrich) in the Odyssey Blocking Buffer (Li-Cor Biosciences,
Omaha, NE) with 0.01% Tween-20 (Sigma-Aldrich) at 4 C overnight. Blots were
then washed in PBST (PBS with 0.1% Tween-20) and incubated with secondary
antibody conjugated to IRDye 800CW or 680CW ﬂuorophore (1/20,000, Li-Cor
Biosciences). Protein bands were detected and acquired for further analysis using
Image Studio (Li-Cor Biosciences). Blot images have been cropped for presenta-
tion. Full-size blots are presented in Supplementary Figs 7 and 8. Total band
intensities were ﬁrst normalized to b-actin, GAPDH or HDAC, and the ratio
between phosphorylated protein and total protein was used to determine the level
of signalling.
Flow cytometry. Peritoneal macrophages from young (o3 months) and old
(418 months) mice were isolated and cultured as described previously.
Macrophages were blocked with mouse BD Fc Block (BD Pharmingen, San Diego,
CA) before double staining with PE-Cy7-conjugated anti-mouse F4/80 (1/100;
25–4,801, clone:BM8, eBiosciences) and anti-mouse IL10R1-PE (1/100; CD210,
no. 559914, clone 1B1.3a, BD Biosciences, San Jose, CA) or rat IgG1,k-PE isotype
control (1/100; no. 554685, clone:R3–34, BD Biosciences). Acquisition was carried
out using LSR-II cytometer (BD Biosciences), and the data were analysed using
FlowJo Software (version 7.6.2).
Laser-induced CNV in mice. The rupture of Bruch’s membrane with an Argon
laser was used to induce CNV in mice as described previously12,14,26,65,66. All mice
used in this study were female and aged between 8 and 16 weeks of age. Brieﬂy,
mice were anaesthetized by injecting ketamine hydrochloride (100mg kg 1) and
xylazine (13.4mg kg 1) i.p., and their pupils were dilated with 1% tropicamide.
Using an argon green laser, three to four laser burns were placed around the optic
nerve (0.1 s, 100mm and 700–800mW, Phoenix Laboratory). Seven days after
injury, mice were anaesthetized and perfused with 100ml of 50mgml 1
ﬂuorescein isothiocyanate-labelled dextran (MW 2,000,000) via the femoral vein.
Eyes were enucleated and ﬁxed immediately in 4% paraformaldehyde for 1 h. Eyes
were then washed with PBS and the choroid was ﬂat mounted onto a glass slide.
The choroidal ﬂat mount was either processed for immunohistochemical analysis
or mounted directly with DAPI-containing mounting media for further imaging
and acquisition using Zeiss LSM510 confocal microscopy. Z-stack images of CNV
spots were then processed in ImageJ (National Institutes of Health) to create
pseudo-volumetric two-dimensional images, and pixel intensity was quantiﬁed
using Metamorph software analysis (Sunnyvale, CA).
For anti-IL10R1 antibody-mediated rescue, mice were injected intravitreally
with either 50mg of either isotype control or anti-IL10R1 antibodies (Serotec). Mice
were treated the day of laser injury and 2 days after CNV induction.
For adoptive transfer of primary macrophage study, peritoneal macrophages
elicited by thioglycollate in either Stat3 (WT) or Stat3F/F;LysMCre were harvested
and allowed to recover in cell culture environment for 48 h. Cells were then
scraped, counted and adjusted to 10 106 cells per 100ml. Eighteen- to 22-month-
old mice were anaesthetized and injected withB5 105 cells per eye immediately
after laser injury was induced.
For the 5,15-DPP-mediated rescue experiment, mice received daily i.p. injection
of drug (15mg kg 1 body weight) or vehicle (DMSO) for 5 days until CNV was
performed. Mice continued to receive daily i.p. injection of same dose until the day
before killing for perfusion and choroidal ﬂat mount processing.
Statistics. Statistical signiﬁcance was analysed by two-tailed Student’s unpaired
t-test and analysis of variance with Tukey Kramer post test with the use of
GraphPad Prism Software (version 5.0). Statistical signiﬁcance was deﬁned as a
P value o0.05.
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